Low Dose Radiotherapy for Osteoarthritis

A Prospective Study of Low Dose Radiotherapy for Osteoarthritis

This single institution, multi-site, single arm prospective study will enroll patients with a history of OA and assess changes in pain and function after treatment with LDRT as measured by patient-reported outcomes.

Study Overview

• Status: Recruiting
• Conditions: Osteoarthitis
• Intervention / Treatment: Radiation: Low Dose Radiation Therapy

Detailed Description

To evaluate the use of select instruments (BPI-SF, LEFS, UEFI, PROMIS Global) to detect changes in pain, function, and well-being in patients with OA who are refractory to or otherwise unable to receive other standard of care therapies.

• Study Type: Interventional
• Enrollment (Estimated): 113
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Marlowe Estioko, BS, MS; Phone Number: 267-343-6483; Email: Marlowe.Estioko@Pennmedicine.upenn.edu
• Study Contact Backup: Name: Sonya George, BS; Phone Number: 267-760-7636; Email: Sonya.George@PennMedicine.upenn.edu

Study Locations

• United States
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19104
      • Recruiting
      • Penn Presbyterian Medical Center
      • Principal Investigator: John Plastaras, MD, PhD
      • Contact: Marlowe Estioko, BS, MS; Phone Number: 267-343-6483; Email: Marlowe.Estioko@Pennmedicine.upenn.edu
      • Contact: Sonya George, BS; Phone Number: 267-760-7636; Email: Sonya.George@PennMedicine.upenn.edu
    • Philadelphia, Pennsylvania, United States, 19104
      • Recruiting
      • Perelman Center for Advanced Medicine
      • Principal Investigator: John Plastaras, MD, PhD
      • Contact: Marlowe Estioko, BS, MS; Phone Number: 267-343-6483; Email: Marlowe.Estioko@Pennmedicine.upenn.edu
      • Contact: Sonya George, BS; Phone Number: 267-760-7636; Email: Sonya.George@PennMedicine.upenn.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• 18 years or older
• Diagnosis of OA >3 months in hips, knees, hands, shoulders, ankles or elbows.
• Refractory to standard of care therapies for OA or those who are being considered for more aggressive interventional treatment such as joint replacement, but more conservative treatment is desired.
• Provision of signed and dated informed consent.

Exclusion Criteria:

• Unable to reasonably complete study instruments.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Single; Participants will complete study intervention which consists of the BPI-SF, PROMIS Global v1.2, UEFI (for those with joint pain of the upper extremity) and/or LEFS (for those joint pain of the lower extremity) at baseline, 3-month and 1-year follow-up following 1 or 2 courses of standard of care LDRT.	Radiation: Low Dose Radiation Therapy; Participants will complete study intervention which consists of the BPI-SF, PROMIS Global v1.2, UEFI (for those with joint pain of the upper extremity) and/or LEFS (for those joint pain of the lower extremity) at baseline, 3-month and 1-year follow-up following 1 or 2 courses of standard of care LDRT.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To measure the percentage of subjects who experience a best response of 1 point or more on BPI-SF	Assess the degree of patient-reported pain prior to and after use of 1-2 courses of LDRT	Within 1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To measure the percentage of subjects who experience a best response of 1 point or more on BPI-SF	Assess the degree of patient-reported pain prior to and after 1 course of LDRT	at ~ 3 months
To measure change in PROMIS scores	Assess the degree of patient-reported global wellness prior to and after use of 1-2 courses of LDRT	From baseline at 3-month and 1-year follow-up
To measure change in LEFS scores as measured	Assess the degree of patient-reported lower extremity function prior to and after use of 1-2 courses of LDRT	From baseline at 3-month and 1-year follow-up
To measure change in UEFI scores as measured	Assess the degree of patient-reported upper extremity function prior to and after use of 1-2 courses of LDRT	From baseline at 3-month and 1-year follow-up

Collaborators and Investigators

• Sponsor: Abramson Cancer Center at Penn Medicine

Study record dates

Study Major Dates

• Study Start (Actual): June 24, 2026
• Primary Completion (Estimated): June 1, 2029
• Study Completion (Estimated): June 1, 2029

Study Registration Dates

• First Submitted: July 15, 2026
• First Submitted That Met QC Criteria: July 15, 2026
• First Posted (Actual): July 20, 2026

Study Record Updates

• Last Update Posted (Actual): July 20, 2026
• Last Update Submitted That Met QC Criteria: July 15, 2026
• Last Verified: July 1, 2026

More Information

Terms related to this study

• Keywords: Osteoarthritis; Low Dose Radiotherapy
• Additional Relevant MeSH Terms: Musculoskeletal Diseases; Arthritis; Joint Diseases; Rheumatic Diseases; Osteoarthritis; Therapeutics; Radiotherapy
• Other Study ID Numbers: UPCC 02025

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No